Peripheral Blood Cytokines and Outcomes with Immune Checkpoint Blockade: a Systematic Review and Meta-analysis

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2024 Aug 19

PMID 39155854

Authors

Alexander B Karol

Yu Fujiwara

Tyler DOvidio

Elena Baldwin

Himanshu Joshi

Deborah B Doroshow

Matthew D Galsky

Affiliations

Soon will be listed here.

Abstract

Tumor-promoting inflammation and inflammatory cytokines are linked to immune checkpoint blockade (ICB) resistance. We assessed the associations between pre-treatment Interleukin-6 (IL-6), Interleukin-8 (IL-8) levels and on-treatment changes in IL-6, IL-8 and C-reactive protein (CRP) with ICB trial end points. 27 studies representing 6,719 patients were included. Low pre-treatment IL-6 levels were associated with improved objective response rate (ORR) (odds ratio (OR) = 0.31 [0.18-0.55]) and better progression-free survival (PFS) (hazard ratio (HR) = 0.59 [0.48-0.72]) and overall survival (OS) [95% confidence interval (CI)] (HR = 0.42 [0.35-0.50]). Low pre-treatment IL-8 levels were associated with improved ORR (OR = 0.47 [0.36-0.61]) and better PFS (HR = 0.65 [0.58-0.74]) and OS (HR = 0.44 [0.39-0.51]). On-treatment decline in CRP was associated with improved ORR (OR = 0.18 [0.11-0.20]), PFS (HR = 0.40 [0.31-0.91]) and OS (HR = 0.48 [0.40-0.58]). Peripheral blood cytokines warrant further evaluation as enrichment and pharmacodynamic biomarkers for strategies targeting tumor-promoting inflammation.

Citing Articles

Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation.

Zhang C, Liu J, Gu T, Meng X, Cai X, Zhang J Breast Cancer Res Treat. 2025; .

PMID: 40050525 DOI: 10.1007/s10549-025-07676-9.

References

Wang M, Zhai X, Li J, Guan J, Xu S, Li Y . The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. Front Immunol. 2021; 12:670391. PMC: 8339552. DOI: 10.3389/fimmu.2021.670391. View

Simeone E, Gentilcore G, Giannarelli D, Grimaldi A, Caraco C, Curvietto M . Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014; 63(7):675-83. PMC: 11028686. DOI: 10.1007/s00262-014-1545-8. View

Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L . Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. J Immunother Cancer. 2022; 10(5). PMC: 9157347. DOI: 10.1136/jitc-2022-004885. View

Shi Y, Liu X, Liu J, Zhang D, Liu X, Yue Y . Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. Transl Lung Cancer Res. 2022; 10(12):4477-4493. PMC: 8743518. DOI: 10.21037/tlcr-21-710. View

Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K . Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. Urol Oncol. 2019; 38(5):526-532. DOI: 10.1016/j.urolonc.2019.12.008. View

Fukuda S, Saito K, Yasuda Y, Kijima T, Yoshida S, Yokoyama M . Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer. 2021; 9(2). PMC: 7896625. DOI: 10.1136/jitc-2020-001564. View

Kijima T, Yamamoto H, Saito K, Kusuhara S, Yoshida S, Yokoyama M . Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2020; 70(3):657-665. PMC: 10991418. DOI: 10.1007/s00262-020-02709-2. View

Tachibana H, Nemoto Y, Ishihara H, Fukuda H, Yoshida K, Iizuka J . Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2021; 20(1):e81-e88. DOI: 10.1016/j.clgc.2021.10.005. View

Laino A, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M . Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020; 8(1). PMC: 7312339. DOI: 10.1136/jitc-2020-000842. View

10.

de Klerk L, Patel A, Derks S, Pectasides E, Augustin J, Uduman M . Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. J Immunother Cancer. 2021; 9(9). PMC: 8487210. DOI: 10.1136/jitc-2021-002472. View

11.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

12.

Shi Y, Liu X, Du J, Zhang D, Liu J, Chen M . Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. Thorac Cancer. 2021; 13(2):219-227. PMC: 8758427. DOI: 10.1111/1759-7714.14248. View

13.

Schalper K, Carleton M, Zhou M, Chen T, Feng Y, Huang S . Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020; 26(5):688-692. PMC: 8127102. DOI: 10.1038/s41591-020-0856-x. View

14.

Naqash A, McCallen J, Mi E, Iivanainen S, Marie M, Gramenitskaya D . Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023; 11(10). PMC: 10603340. DOI: 10.1136/jitc-2023-007310. View

15.

Tomita Y, Larkin J, Venugopal B, Haanen J, Kanayama H, Eto M . Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. ESMO Open. 2022; 7(5):100564. PMC: 9588905. DOI: 10.1016/j.esmoop.2022.100564. View

16.

Myojin Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y . Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. Cancers (Basel). 2022; 14(4). PMC: 8870238. DOI: 10.3390/cancers14040883. View

17.

Harutani Y, Ozawa Y, Murakami E, Sato K, Oyanagi J, Akamatsu H . Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors. Cancer Immunol Immunother. 2022; 71(9):2109-2116. PMC: 10991224. DOI: 10.1007/s00262-022-03141-4. View

18.

Chasseuil E, Saint-Jean M, Chasseuil H, Peuvrel L, Quereux G, Nguyen J . Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma. Acta Derm Venereol. 2018; 98(4):406-410. DOI: 10.2340/00015555-2872. View

19.

Kang D, Park C, Chung C, Oh I, Kim Y, Park D . Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors. Immune Netw. 2020; 20(3):e27. PMC: 7327149. DOI: 10.4110/in.2020.20.e27. View

20.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View